Azacitidine: Difference between revisions
From IDWiki
(Created page with "* Cytidine analogue used to treat myelodysplastic syndrome and acute myelogenous leukemia * Can cause cytopenias and hepatotoxicity and renal toxicity Category:Medi...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
* Cytidine analogue used to treat [[myelodysplastic syndrome]] and [[acute myelogenous leukemia]] |
* Cytidine analogue used to treat [[myelodysplastic syndrome]] and [[acute myelogenous leukemia]] |
||
* Can cause cytopenias and hepatotoxicity and renal toxicity |
* Can cause cytopenias and hepatotoxicity and renal toxicity |
||
*Infectious complications include [[febrile neutropenia]] |
|||
*Bacterial infections are common, including [[pneumonia]], [[URTI]], [[cellulitis]], [[bacteremia]], [[Urinary tract infection|urinary tract infections]], [[Intra-abdominal infection|intraabdominal infections]] (in descending order of frequency)[[CiteRef::trubiano2017in]] |
|||
**Viral infections and fungal infections (including [[invasive aspergillosis]]) are also possible complications |
|||
[[Category:Medications]] |
[[Category:Medications]] |
||
Latest revision as of 15:45, 24 February 2022
- Cytidine analogue used to treat myelodysplastic syndrome and acute myelogenous leukemia
- Can cause cytopenias and hepatotoxicity and renal toxicity
- Infectious complications include febrile neutropenia
- Bacterial infections are common, including pneumonia, URTI, cellulitis, bacteremia, urinary tract infections, intraabdominal infections (in descending order of frequency)1
- Viral infections and fungal infections (including invasive aspergillosis) are also possible complications
References
- ^ Jason A. Trubiano, Michael Dickinson, Karin A. Thursky, Timothy Spelman, John F. Seymour, Monica A. Slavin, Leon J. Worth. Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leukemia & Lymphoma. 2017;58(10):2379-2386. doi:10.1080/10428194.2017.1295141.
